Neuronetics, Inc. STIM
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Neuronetics, Inc. is a U.S.-based medical technology company focused on neurohealth therapies, primarily through non-invasive neuromodulation technologies used in psychiatry. The company operates in the healthcare and medical device industries and is best known for its NeuroStar Advanced Therapy platform, a transcranial magnetic stimulation (TMS) system cleared by the U.S. Food and Drug Administration for the treatment of major depressive disorder and certain other mental health conditions. Revenue is primarily generated through the sale and lease of NeuroStar systems, recurring treatment session revenues tied to treatment utilization, and sales of treatment accessories and service agreements.
Neuronetics primarily serves psychiatric practices, hospitals, behavioral health clinics, and mental health providers in the United States, with expanding international activity through distribution relationships. The company positions itself as a leader in the TMS market through clinical evidence, installed base scale, payer coverage expansion, and recurring revenue generated from treatment utilization. Founded in 2003 and headquartered in Malvern, Pennsylvania, the company evolved from an early-stage neuromodulation developer into a commercial-stage medical device business following FDA clearance of NeuroStar in 2008 and its subsequent public listing on Nasdaq under the ticker STIM in 2018.
Business Operations
Neuronetics conducts operations primarily through its commercial neurostimulation platform business centered around NeuroStar Advanced Therapy. The company’s operating activities include direct device sales, operating leases, treatment session utilization fees, service contracts, and sales of associated treatment components. Its business model combines capital equipment deployment with recurring procedural revenue, creating an installed-base-driven revenue structure. The company’s core assets include proprietary TMS technology, software-enabled treatment management systems, clinical data resources, and intellectual property related to magnetic neurostimulation therapy delivery.
The company’s operations are concentrated mainly in the United States, where most revenue is generated through direct commercial activities, reimbursement-supported psychiatric treatment networks, and physician office placements. Internationally, Neuronetics has historically utilized distributor relationships in selected markets rather than broad direct operations. Strategic relationships with mental health providers, healthcare systems, and reimbursement stakeholders are important to its commercial strategy. Public filings and investor materials identify expanding patient access, treatment awareness, and provider adoption as central operational priorities.
Strategic Position & Investments
Neuronetics’ strategic direction has focused on expanding adoption of TMS therapy, increasing recurring treatment revenue, and broadening clinical applications for its technology platform. The company has invested in commercial expansion, digital workflow tools, patient engagement technologies, and clinical research intended to strengthen physician adoption and payer acceptance. Growth initiatives have included increasing system placements among psychiatric practices and improving treatment throughput and utilization among existing customers.
The company has also pursued strategic acquisitions and portfolio expansion to strengthen its position within behavioral health technology. In 2024, Neuronetics announced the acquisition of Greenbrook TMS Inc., a TMS treatment center operator, in a transaction designed to vertically integrate treatment delivery capabilities and expand patient access infrastructure. Public disclosures indicate continued emphasis on neurohealth innovation, evidence generation, reimbursement expansion, and broader integration of non-drug therapies into mental healthcare delivery. The company remains closely associated with the emerging field of device-based psychiatric treatment and non-invasive brain stimulation technologies.
Geographic Footprint
Neuronetics is headquartered in Malvern, Pennsylvania, and derives the substantial majority of its revenue from the United States healthcare market. Its installed systems are primarily deployed across U.S. psychiatric and behavioral health practices, hospitals, and treatment centers. The company’s commercial infrastructure, reimbursement engagement efforts, and provider support operations are centered domestically due to the importance of insurer coverage and physician adoption in the U.S. TMS market.
Outside the United States, Neuronetics has maintained a more limited but expanding international presence through third-party distributors and regulatory clearances in selected countries. Its international footprint has included parts of North America, Europe, Asia-Pacific, and the Middle East, although overseas operations remain smaller relative to its domestic business. Public company filings indicate that international revenue historically represented a minority share of total revenue.
Leadership & Governance
Neuronetics is led by an executive team with backgrounds in medical devices, healthcare commercialization, psychiatry-related technologies, and operational management. The company operates under a publicly traded corporate governance structure overseen by a board of directors and subject to U.S. public company reporting standards, including disclosures in SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Leadership strategy has emphasized commercial execution, reimbursement expansion, clinical evidence development, and scaling access to non-invasive mental health therapies.
Key executives include:
- Keith J. Sullivan – President and Chief Executive Officer
- Stephen Furlong – Senior Vice President, Chief Financial Officer, and Treasurer
- Richard Buchholz – Senior Vice President, Sales
- Chris Thatcher – Senior Vice President, Marketing
- David Hallal – Chairman of the Board
The company’s leadership has consistently communicated a strategy centered on increasing awareness and adoption of TMS therapy as an alternative or adjunctive treatment for depression and related psychiatric conditions, while strengthening recurring revenue generation and expanding the company’s neurohealth platform capabilities.